Market Capitalisation million 24 25 the shares SkyePharmas shares are listed on the London Stock Exchange where the ticker symbol is SKP.
The companys American Depository Receipts ADR are listed on the US NASDAQ exchange ticker symbol SKYE.
One ADR represents 10 ordinary shares.
Fig 1: Ownership distribution as at 31 December 2003 Share price performance Number of shares Number of shareholders % of shareholders % of share capital After a dismal performance in 2002, world stock markets showed a strong recovery in 2003, marking Less than 1,000 8,798 44.9 0.8 the end of a three year bear market.
Despite the 1,001 10,000 9,410 48.0 5.1 uncertainties posed by the Iraq invasion, growing investor confidence resulted in a reversal from the 10,001 100,000 1,117 5.9 4.9 oversold position at the end of 2002, particularly 100,001 1,000,000 208 1.1 11.8 evident in the smaller capitalisation technology 1,000,001 10,000,000 61 0.3 36.3 stocks that had under-performed so dramatically in the 2000-2002 period.
As an example, the US Above 10 million 10 0.1 41.1 Dow Jones Industrial Average index rose by 25% in 2003 whereas the technology-rich NASDAQ Fig 2: Ten largest shareholders as at 31 December 2003 composite index soared by 50%.
SkyePharma Shareholder shareholding million % of share capital benefited from this trend, with the share price nearly doubling, even though the pharmaceutical Fidelity Investments 83.0 13.4 sector was generally out of favour.
Dr J Gonella 42.0 6.8 During 2003, SkyePharmas share price rose by ADRs 41.0 6.6 81% from 41.5 pence to 75.25 pence.
The years Standard Life Investments 31.8 5.1 low was 41.5 pence in February and the high Kowa Company 30.0 4.9 79.25 pence in November.
For comparison, the broad FTSE All-share index rose by 14% in 2003.
Legal & General Investment Management 21.1 3.4 The figure below shows that SkyePharma shares Axa Investment Managers 16.9 2.7 broadly moved in line with the UK market in 2002 but significantly outperformed during the Oppenheimer Funds 13.9 2.3 stockmarket recovery in 2003.
Royal London Asset Management 11.9 1.9 Merrill Lynch Investment Management 11.3 1.8 During 2003 the FT Pharmaceutical and Biotechnology sector index dominated by The investor holding information in this table is derived from our analysis of the share register, which combines pharmaceutical companies rose by 13%, in line shareholding data and the responses to our enquiries issued under Section 212 of the Companies Act 1985. with the market as a whole.
The Biotechnology The reported institutional shareholdings may therefore include funds which are non-beneficially owned and or those which are managed on a discretionary basis by the investor.
As such some institutional shareholdings sector did better, with an increase of 35%.
stated may differ from the figures reported by those institutions on a beneficial ownership basis only.
The figure below indicates that in the period 2002-2003 SkyePharma comfortably outperformed not only the Pharmaceutical Distribution of Non-UK Shareholdings by Country Italy 1.2% Denmark 2.2% SkyePharma Market Capitalisation 2003 Finland 2.7% 500 Netherlands 3.2% 450 Luxembourg 4.0% 400 Germany 4.9% 350 Switzerland 19.2% 300 250 Canada 24.8% 200 USA 33.9% Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 05 10 15 20 25 30 SkyePharma SkyePharma annual report 2003 % change from 1 1 02 % change from 1 1 02 sector but also the European Biotechnology of the companys ADRs, believed to be primarily the companys access to capital markets.
Fig 1 shows the All information disseminated to institutional distribution of share ownership.
investors and analysts by print, email or fax is The release of our Trading Update in early simultaneously made available on our website January, disclosing that our 2003 revenues During 2003, there have been significant changes www.
com so that private investors and profits would be significantly below market in the composition of SkyePharmas largest have equal access.
We also webcast our regular expectations because of delays to completion shareholdings.
The international fund manager meetings and teleconferences with analysts of certain new agreements, resulted in an initial Fidelity has become the largest shareholder, and investors.
decline in the share price of approximately 20%.
holding 83 million shares 13.4% of the issued As of 5 May the share price was 58 pence, share capital at the end of the year.
This was SkyePharma takes a proactive stance on investor 28% below the end-2003 level.
a substantial increase since at the beginning of relations, with investor relations offices in London October 2003 Fidelity only held 4 million shares.
In 2003 we held 277 one-on-one Market Capitalisation Fidelity has subsequently further increased its meetings with shareholders or potential investors.
On 31 December 2003, SkyePharmas market holding and as of 1 April held approximately The vast majority of these included an executive capitalisation was 465 million US$830 million, 88 million shares 14.2%.
At the end of 2003, management representative.
In addition compared with 255 million US$411 million Dr Jacques Gonella, the founder of JAGO and SkyePharma participated in 8 investment a year earlier.
The chart below shows the trend a former director of SkyePharma, was the second conferences in the USA and Europe during in the companys market capitalisation largest holder with 42 million shares 6.8% of the year.
The investor relations section of the during 2003. the issued share capital and the third largest companys website attracted over 43,000 hits shareholder was Standard Life with 32 million in 2003.
As of 31 December 2003, the SkyePharmas issued share capital at the end 10 largest shareholders collectively owned Analyst coverage of 2003 amounted to some 619 million shares 306 million shares 49% of the issued share The sell-side analysts listed below currently against 613 million shares at the end of 2002. capital see Fig 2. issue regular reports on SkyePharma.
Please In addition the company had 52 million share note that any opinions, estimates or forecasts options outstanding and certain contingent At the end of 2003, 52% of SkyePharmas shares regarding SkyePharma made by these analysts shares and warrants.
The companys share were held by UK shareholders.
The proportion are theirs alone and do not represent opinions, option scheme aims to incentivise staff and of shares owned by individuals or legal entities forecasts or predictions of SkyePharma or to align shareholder and management objectives.
domiciled outside the UK was 48%.
The bar chart its management.
SkyePharma does not by Conversion of the convertible bonds due in below shows the percentage distribution of the its reference below or distribution imply its June 2005 would involve the issue of a further shares held by non-UK shareholders by country endorsement of or concurrence with such 72 million shares.
of domicile, with the USA being the most important information, conclusions or recommendations.
country followed by Canada and Switzerland.
CODE Securities Paul Diggle Shareholders Credit Suisse First Boston Genghis Lloyd-Harris At the end of 2003, SkyePharma had 19,600 Investor relations Dresdner Kleinwort Benson Shawn Manning shareholders.
Share ownership in SkyePharma It is the objective of SkyePharmas management Evolution Beeson Gregory Jonathan Senior is concentrated, with the top 10 shareholders and investor relations team to ensure a timely, ING Barings Richard Parkes owning about half of the shares and the 25 largest open, comprehensive and consistent flow of Merrill Lynch James Culverwell Rachna Upadhya shareholders owning approximately two-thirds.
information to investors and the financial SG Cowen Kevin Scotcher Ian Sanderson Approximately 60% of SkyePharmas shares community.
By this means we aim to help Panmure Gordon Keith Redpath were held by institutional or corporate investors investors to understand the companys activities these analysts have resigned since the end of 2003 and 40% by private individuals including holders and strategic objectives and thereby facilitate but replacements are being recruited SkyePharma vs FT Pharma & Biotech SkyePharma vs FT All-share Index 2002-03 and European Biotech Indices 2002-03 40 40 30 -40 20 20 10 10 0 0 -10 -20 -10 -30 -20 -40 -30 -50 -60 -40 Jun Dec Jan Jun Dec Jan Jun Dec Jan Jun Dec Jan 02 02 03 03 03 02 02 03 03 03 02 02 SkyePharma FT All-share Index SkyePharma FT Pharma & Biotech Index European Biotech Index SkyePharma annual report 2003
